Introduction
The roles of the N-terminal region of seven transmembrane receptors (7TMRs) in receptor functions, such as ligand binding, surface expression, signaling, and desensitization, vary depending on the size and structure of the N-terminus. It is well established that in some 7TMRs, the N-terminus participates in cognate agonist binding and activation. These 7TMRs include secretin-like (family 2), metabotropic glutamate-like (family 3), and the rhodopsinlike (family 1) 7TMRs that bind peptides. Within this latter family, the N-terminal domain interaction with the core of the receptor has been associated with different modes of activation. For protease-activated receptors, cleavage of an N-terminal inhibitor initiates receptor activation (Ramachandran and Hollenberg, 2008) . For glycoprotein hormone receptors, activation is dependent on the release of constitutive inhibition upon binding of a ligand to the N-terminus of the receptor (Vassart et al., 2004) . For the melanocortin MC4R, a diffusible inverse agonist inhibits N-terminal activation (Ersoy et al., 2012; Srinivasan et al., 2004) . However, the N-terminal regions of the rhodopsin-like 7TMR family interacting with such small ligands as monoamines have been the least studied among the superfamily, and their roles in agonist-induced signaling and desensitization have not been reported.
In some 7TMRs, such as the cannabinoid CB1 receptor, α 1-adrenergic receptor, and GPR37, published data show that truncation of the N-terminal region increases plasma membrane expression of these receptors (Andersson et al., 2003; Dunham et al., 2009; Hague et al., 2004) . The extracellular surface of biogenic amine 7TMRs affects ligand recognition, ligand 'escorting' into the binding pocket, and ligand binding kinetics (Wittmann et al., 2011) .
We previously observed that deletion of the long N-terminus of the Drosophila 5-HT 2Dro receptor (which most closely resembles the mammalian 5-HT 2B receptor) affects its pharmacology, with some compounds exhibiting a 10-fold change in affinity (Colas et al., 1997) . This early finding suggested that the N-terminus affects the conformation of the
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receptor transmembrane (TM) regions involved in ligand interactions, which may be relevant for receptor structure, because modelers usually exclude (often for technical reasons) 7TMR N-termini including the recently published crystal structures for 5-HT 2B receptors (Wacker et al., 2013) . These observations suggested that the N-terminal regions of 7TMRs modulate the activity of biogenic amine 7TMRs by as-yet uncharacterized mechanisms.
Drug abuse vulnerability is a complex trait with strong genetic influences.
Understanding the genetic bases of drug abuse vulnerability and particular allelic variants that contribute to this vulnerability can strongly improve our understanding of human addictions.
We have recently extended the role of serotonin (5-hydroxytryptamine, 5-HT) in the behavioral responses to psychostimulants by revealing that the genetic ablation of Htr 2B in mice, the gene encoding 5-HT 2B receptors, eliminates locomotor response and place preference induced by (±)-3,4-methylenedioxymethamphetamine (MDMA) (Doly et al., 2009; Doly et al., 2008) . Independently, three novel single nucleotide polymorphisms, two of which result in a point mutation, were described in a drug-abusing population (Lin et al., 2004) . The
Arg6, a conserved basic residue, and the conserved acidic Glu42 are mutated simultaneously into Gly, termed R6G;E42G.
Starting from these observations, the present work aimed to establish whether these polymorphisms within the 5-HT 2B receptor N-terminus affect receptor pharmacology. We discovered a new and unanticipated function of this extracellular region; i.e., it acts as a negative structural modulator of receptor basal and stimulated activity.
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Materials and Methods
Plasmid constructs-Human 5-HT 2B receptor cDNA was subcloned into the p513 vector, a derivative of the pSG5 mammalian expression vector (Green et al., 1988) , which replicates in SV40 T antigen-transformed cells and drives 5-HT 2B receptor expression under the control of the SV40 early promoter. N-terminal variant 5-HT 2B receptors were generated using the Quickchange II (Stratagene, La Jolla, CA, USA) site-directed mutagenesis kit according to the manufacturer's protocol. The N-terminal truncated 5-HT 2B receptor mutant was generated by PCR deletion mutagenesis. TM1 constructs carrying different N-terminal sequence were obtained from each full construct by removing a PstI-PstI fragment (from AA85 to the Cterminal end of the 5-HT 2B receptor sequence).
TM1-tethered (WT, R6G;E42G or Δ Nter) and Δ Nter 5-HT 2B receptor coding regions were amplified from their respective cDNAs using appropriate sense and antisense primers.
The fragments were then subcloned in frame in either a plasmid encoding C-terminus YFP (Clontech/BD Biosciences, Mountain View, CA) or Renilla luciferase (Rluc). The coding regions of all constructs were entirely sequenced. The Rluc construct was a kind gift from Stefano Marullo (U1016, Institut Cochin, Paris).
Cell culture-COS-7 cells were cultured as monolayers in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Biowest) and 1% penicilin/streptomycin (Sigma, St Louis, MO, USA), in 9-cm dishes (Falcon). Cells were incubated at 37°C in a 5%CO 2 atmosphere. Cells were 80% confluent when transfected with 10µg of DNA using Nanofectin (PAA), according to the manufacturer's protocol, in an antibiotic-free medium. Four hours later, medium was replaced with fresh medium. Twenty-four hours after transfection, cells were incubated in serum free medium for membrane radioligand binding or trypsinized (Trypsin 1X 0.05% EDTA,
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Invitrogen) and plated onto 24-well plates for IP accumulation and whole cell radioligand binding.
[ 3 H]Thymidine incorporation assay-Proliferation as measured by incorporation of radioactive desoxythymidine incorporation was performed as previously described (Deraet et al., 2005) . Desensitization Assay-To evaluate receptor desensitization, IP accumulation assays were performed as described above, except that a first agonist stimulation, in the absence of LiCl (to avoid IP accumulation), occurs at different time points (15, 30, 45, 60, 90 and 120 minutes) before a second stimulation with 100 nM of DOI. After the first stimulation, the medium was removed, the cells were washed three times with fresh medium, and fresh medium containing LiCl + DOI (100 nM) was added. The end of the experiment was carried out as previously described, and data were also normalized by each control condition, i.e.
without the first stimulation (time 0 min). At least three independent experiments were performed in duplicate.
Membrane Radioligand Binding Assay-Membrane binding assays were performed on transfected cells plated in 9 cm dishes. Cells were first washed with PBS and scraped into 10 ml of PBS on ice, then centrifuged for 5 min at 1,000 g. Cell pellets were dissociated and lysed in 2 ml of binding buffer (50 mM Tris HCl, 10 mM MgCl 2 , 0.1 mM EDTA, pH 7.4) and centrifuged for 30 min at 10,000 g. Membrane preparations were then resuspended in binding buffer to obtain a final concentration of 0.2-0. accurately determine affinity and efficacy since a drug that binds with high affinity but has low efficacy will produce the same dose-response curve as a drug with low affinity and high efficacy. To untangle affinity from efficacy, we used the operational model initially described by (Black and Leff, 1983) , which defines response as:
where E m represents the maximal response capability of the system, K A is the equilibrium dissociation constant of the agonist-receptor complex, n is the slope of the dose-response curve and τ is the efficacy. This final term represents the receptor density and molecular interaction of the agonist-receptor complex interaction with the stimulus-response system of the cell, which itself has ligand-specific elements (efficacy of the ligand) and system-specific elements (efficiency of coupling of receptors to signalling pathway). A theoretically complete term to describe the power of a ligand to active a cellular pathway is the term τ /K A ; this incorporates both elements of efficacy and affinity. Considering that the most common difference between systems is receptor density, ratios of τ /K A account for these and should be system-independent measures of the relative power of ligands to activate pathways.
Another useful measure of agonist activity is Ehlert's "activity ratio" (denoted RA). Both affinity and efficacy for a single number of agonism for dose-response curves of unit slope have been solved with the application of relative activity (RA) ratios. Proposed by Ehlert and
colleagues (Ehlert, 2005) , the RA value is the maximal response of the agonist divided by the EC50. This furnishes a single number reflecting the power of a molecule to produce agonism in any system. In terms of the maximal response and EC 50 for dose-response curves in the Black Leff operational model (Black and Leff, 1983) , it can be shown that RA represents the relation:
For dose-response curves of unit slope (n = 1), it can be seen that RA reduces to the term 
Results
The N-terminus of the 5-HT 2B receptor affects agonist affinity.
Starting from the report by Lin et al. (Lin et al., 2004) , we explored the pharmacological properties of the R6G;E42G variant 5-HT 2B receptor, which contains two amino acid (AA) changes in the N-terminal region (Fig. 1) . To study the effect of the N-terminal mutations, we compared wild type (WT) and variant 5-HT 2B receptor-transfected COS-7 cells using radioligand binding assays. Homologous competition experiments showed a left shift in the displacement curve for 5-HT binding (Fig. 2a) . The 5-HT 2B variant receptor had a five-fold increase in affinity for 5-HT; i.e., a five-fold decrease in the K i for the R6G;E42G (p < 0.05) variant relative to the WT receptor ( Table 1) . Using the 5-HT 2B/2C receptor-selective agonist BW723C86 as a competitor, a four-fold increase in affinity was found compared to WT receptor ( Table 1) . A similar effect was observed using the 5-HT 2 agonist DOI as a competitor, which displayed a 2.4-fold increase in affinity for the N-terminal variant receptor compared to the WT. Because none of the tested antagonists were affected by the SNPs (Table 1-Fig. 2b) , it was likely that the mutations affect receptor coupling. However, the fact that only some of the tested agonists are affected by this variant may be related to a probe dependence issue, agonism being a combined interaction of the modulator (agonist), receptor and signaling protein, known to be probe dependent. Nevertheless, this gain of affinity seems independent of the type of agonism, full agonists being not differentially affected compared to partial agonists ( Table 1- Cussac et al., 2008) . In light of the finding that N-terminal deletion of the 5-HT 2Dro affected the affinity of some agonists (Colas et al., 1997) , we tested the effect of N-terminal deletion the first 32 AAs of the human 5-HT 2B receptor ( Fig. 1) (ΔNter).
Interestingly, this N-terminal truncation generated an apparent shift in agonist affinity, with a 30-fold increase in affinity for 5-HT (Fig. 2a) . Because the R6G;E42G variant results in neutralization of two oppositely charged AA side chains, we hypothesized that these residues
interacted electrostatically. Based on this, we tested whether exchanging the position of the charged residues would alter 5-HT 2B receptor ligand affinity vis-à-vis the WT receptor. Thus, we generated the 'charge swap' mutant R6E;E42R. This inversion also increased its apparent affinity for 5-HT (Fig. 2a) , indicating that a missing electrostatic interaction in the R6G;E42G variant likely affects its pharmacological properties.
The N-terminus of the 5-HT 2B receptor can modulate receptor-Gαq activation.
We then explored the impact of N-terminal modifications on an immediate effector of 5-HT 2B receptors, the Gαq/11-sensitive membrane phospholipase C (PLC). Upon agonist binding, the 5-HT 2B receptor stimulates hydrolysis of membrane phosphatidyl inositol-bisphosphate (PIP 2 )
into cytoplasmic inositol phosphates (IP 3 , which promotes intracellular calcium release, and the degradation products IP 2 and IP 1 ) and diacylglycerol (an activator of protein kinase C) (Deraet et al., 2005) . Since the N-terminal mutations may affect cell surface expression, we evaluated the cell surface expression as receptor B max using tritiated mesulergine competition comparing purified membrane to non-permeabilized whole cells binding (Supplemental Fig.   1 ). Only a fraction of the total membrane binding capacity was found on whole cells, supporting the rationale to used whole cell B max as an estimate of surface receptor to normalize coupling efficiency.
Integrating these B max values to normalize for surface receptor expression, increasing concentrations of a partial 5-HT 2 agonist, DOI, activated the R6G;E42G variant more efficaciously than the WT receptor, leading to a increase of both minimal (E min +48%) and maximal (E max +56%) cytoplasmic IP accumulation, as well as activation efficiency (E max -E min ), with little effect on apparent agonist potency EC 50 (Fig. 2c) . The N-terminal deletion of the first 32 AAs (ΔNter) also generated an increase in IP basal activity (ΔNter 68%). DOI also induced a stronger 5-HT 2B receptor-mediated IP accumulation as did basal 5-HT 2B receptor-
mediated PIP 2 hydrolysis, with a noticeable increase for the Δ Nter mutant (ΔNter 97%), while the inverse mutant displayed a moderate increase in E max (15%) (Fig. 2c) . This basal activity was tested against a known inverse agonist for the receptor, ritanserin, which was able to reverse this basal activity to similar extent (Supplemental Fig. 2a ). Other tested agonists followed the same trend as DOI, activating the R6G;E42G variant receptor more efficaciously than the WT receptor (+25% for 5-HT, p < 0.05; +17% for dexfenfluramine -DF, p < 0.01; +20% for nordexfenfluramine -NDF, p < 0.05; +21% for DOI, p < 0.001 and +30% for MDMA, p < 0.05) (Supplemental Fig. 2b-e) . Taken together, these results indicate that the human R6G;E42G polymorphism leads to increased coupling of the 5-HT 2B receptor to phospholipase C activity. Notably, the IP responses for the R6G;E42G variant were significantly increased for DOI as well as for other agonists including MDMA, DF, and its metabolite NDF.
Validation using the operational model of the modulation by the N-terminus of the 5-HT 2B receptor-Gαq activation.
To take into account putative alteration of the efficiency of receptor coupling, which may vary among the mutants, we used the Black-Leff operational model to derive Ehlert's "activity ratio" (denoted RA) (Ehlert, 2005) , the RA value is the maximal response of the agonist divided by the EC50 and calculate putative difference in signaling characteristics for IP production for each mutant as ∆ ∆ Log(RA) (Black and Leff, 1983; Ehlert, 2005; Kenakin et al., 2012 Section, Fig. 3a,b,c, and supplemental Fig. 3 ). The data shows that the R6G;E42G and R6E;E42R mutations produced significant differences in the relative way 5-HT and DOI bind to and active the receptor. These show statistically significant differences between the relative activity of 5-HT and DOI produced by the R6G;E42G mutation (DOI was more active when compared to 5-HT) (Fig. 3c) . The R6E;E42R mutation (DOI was relatively less active when compared to 5-HT) and the ∆ Nter mutation produced little effect in the way 5-HT and DOI interact (or at the least, the changes induced by the mutation are the same for both probes) (Supplemental Fig. 3 ).
So far, the results obtained by two independent approaches support a role for the Nterminus variant R6G;E42G in controlling the efficacy and affinity of DOI-stimulated 5-HT 2B
receptor-mediated PIP 2 hydrolysis, suggesting that the two AA substitutions encoded by this polymorphism are sufficient to modify N-terminal function over the receptor.
Validation of N-terminal domain interactions
Further evidence for the involvement of the 5-HT 2B N-terminus in receptor function was obtained using dual genetic constructs: the first TM domain of the 5-HT 2B receptor (TM1) was used as a membrane tether for various N-terminal sequences and was co-transfected with N-terminally truncated receptors ( Fig. 4a-i) to explore putative intermolecular (in trans)
effects. The underlying hypothesis was that expression of the TM1-tethered WT N-terminus could interact and thus suppress the effect of N-terminal truncation on receptors by direct interactions.
In order to first validate putative interactions between TM1-tethered construct and 7TMR, COS-7 cells were cotransfected with plasmids coding for ∆ Nter 5-HT 2B receptor and TM1-tethered (WT, R6G;E42G or Δ Nter)-YFP. Confocal analysis using a 5-HT 2B receptor antibody revealed colocalization with the YFP for all tested TM1-tethered (WT, R6G;E42G (Fig 4a-i) . This observation supports the putative close localization between these different receptor fragments upon co-expression. Proper membrane expression of the TM1-tethered N-terminus was also verified by immunofluorescence and confocal microscopy on non-permeabilized cells using an antibody raised against the N-terminus of the human 5-HT 2B receptor (Fig. 4j,k) .
To validate putative interactions between the TM1-tethered construct and N-terminally (Fig 5A-D) . This result further supports protein-protein interactions between the various receptor constructs.
Interactions between TM1-tethered (WT, R6G;E42G or Δ Nter) constructs and Δ Nter 5-HT 2B receptor were further examined in living COS-7 cells using bioluminescence resonance energy transfer (BRET). Δ Nter 5-HT 2B receptor fused to Rluc (ΔNter 5-HT 2B -Luc) was expressed in the presence of increasing concentrations of BRET acceptors, consisting of TM1-tethered WT, R6G;E42G or Δ Nter linked to cytoplasmic YFP. In all cases, hyperbolic saturation curves were obtained, further supporting protein-protein interactions (Fig 5E-H control; only a linear nonspecific BRET signal was obtained confirming the specificity of the observed interactions.
Functional impact of N-terminal domain interactions
We then evaluated the functional impact receptors measured through the average E min and E max for IP accumulation after DOI stimulation first for the WT receptor (Fig. 6A) after correction for the protein input and for the surface receptor B max . We evaluated similarly E max for IP accumulation after DOI stimulation of each combination of constructs (Fig 6B) . was co-transfected with the Δ Nter receptor, intracellular IP accumulation was significantly decreased, becoming non-significantly different from WT level (Fig. 6C) . However, IP accumulation was still increased (>130% WT level) when the Δ Nter receptor was cotransfected with a TM1 construct carrying the variant mutation (TM1-R6G;E42G). This result indicates that tethered expression of a WT N-terminus (TM1-WT) is able to restore the WT activity in trans (Fig. 6C) . Although able to interact biochemically, the lack of effect for the MOL #89086 p 2 0 TM1-tethered R6G;E42G fragment clearly demonstrates the loss of N-terminus functionality in the variant receptor.
Functional impact of N-terminal domain variant on other transduction pathways.
In addition to IP coupling, we previously showed that the 5-HT 2B receptor can activate cell proliferation via both Gαq/11 and Gα13 (Deraet et al., 2005) . We therefore assessed whether the polymorphism in the N-terminal sequence modifies the proliferative function of the 5-HT 2B receptor as measured by [ 3 H]thymidine incorporation (Fig. 7A) . Interestingly, in response to 1 µM 5-HT, COS-7 cells expressing the R6G;E42G variant incorporated five times more thymidine than did cells transfected with WT receptor. This observation suggests that the 5-HT 2B N-terminus is important for additional effector pathways including proliferation.
Finally, we observed that the gain-of-function dual SNP altered the desensitization process of the receptor. We evaluated the desensitization kinetics of the receptor variant by first challenging with DOI in the absence of LiCl (no IP accumulation) and then, after extensive washing, repeating the DOI challenge at various time points in the presence of LiCl. As shown in Figure 7B , the receptor variant desensitized more slowly than did the WT receptor, consistent with a modified signal transduction capacity of the polymorphic 5-HT 2B receptor.
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Discussion
We report a functional study of two HTR 2B SNPs that modify two amino acids (R6G;E42G) within the N-terminus of the receptor. The polymorphisms were previously identified in drugabusing patients. We show that the R6G;E42G variant of the 5-HT 2B receptor displays increased agonist affinity and efficacy, as highlighted by an increased basal activity E min and increased E max of agonist-induced IP production after normalization by protein content and cell surface receptor expression Bmax or in the black-Leff operational model. Furthermore, this variant also increases the ability of the receptor to trigger cell proliferation and leads to decreased desensitization kinetics.
Historically, rhodopsin-like 7TMRs have been identified and studied on the basis of their ability to be activated by high-affinity diffusible pharmacological ligands interacting directly with the core transmembrane region of the receptor. Interestingly, we found in this study that R6G;E42G 5-HT 2B receptors are more efficiently coupled to G proteins than are WT receptors, as shown by agonist binding and functional assays. Using various TM1-tethered N-termini co-expressed with Δ Nter receptor, we demonstrate that these TM1-tethered N-termini can interact with the 7TM domains using complementary approaches:
colocalization in fixed cells, coimmunoprecipitation in solubilized lysates, and BRET experiments on living cells. Furthermore, when the Δ Nter receptor was co-transfected with a TM1 construct carrying the WT N-terminus, coupling was reversed to WT levels, indicating that tethered expression of a WT N-terminus was able to reverse the gain of coupling due to the deletion of the N-terminus from the 5-HT 2B receptor. This was not observed when the Δ Nter receptor was co-transfected with a TM1 construct carrying the variant mutation (TM1-R6G;E42G). Thus, the N-terminus can alter the coupling efficiency of the receptor in trans.
Structural basis of 7TMR oligomerization have been recently obtained in β 1-adrenergic receptors . In an inactive conformation, two dimer interfaces were MOL #89086 p 2 2 identified: one involving TM1, and the other engaging residues from TM4 and TM5 . Previous findings using biochemical approaches have identified similar interactions in 5-HT 2C receptors (Mancia et al., 2008) . It is thus not totally surprising that, using TM1-tethered N-terminal constructs, we found direct interactions with the 7TM receptor. However, the fact that these interactions were able to modulate basal and agoniststimulated receptor activity was not anticipated. Recently solved crystal structures have directly confirmed previous findings that biogenic amine 7TMRs including 5-HT 2B receptors bind endogenous ligands within the TM helical bundle of the receptor (Manivet et al., 2002; Setola et al., 2005; Wacker et al., 2013) . Conventional agonists target the same binding site on a receptor as the endogenous ligand, termed the orthosteric site (Smith et al., 2011) . Our results support the view that the 5-HT 2B receptor N-terminus, by interacting with TM and/or extracellular loops, acts negatively on coupling efficiency in both basal and stimulated conditions without directly interfering with the orthosteric site. Thus, we propose that the 5-HT 2B receptor N-terminus behaves as a negative structural modulator of the receptor activation. The fact that the R6G;E42G variant also increases the ability of the receptor to trigger cell proliferation and leads to a decreased desensitization kinetic indicates that this modulation acts generally on the receptor activation process, rather than specifically affecting certain intracellular signaling pathways.
These findings extend those of previous studies that have demonstrated a role for the Nterminus in the function of rhodopsin-like 7TMRs. An interaction between the N-terminus and the ECL3 of CXCR4 and C5aR has also been implicated in an activation micro-switch region: whereas the N-terminus/ECL3 interaction stabilizes the active state of CXCR4, it acts as an inverse agonist in C5aR, possibly by making multiple contacts with the TM domains to stabilize the inactive state (Rana and Baranski, 2010) . Furthermore, the N-terminus of histamine H1 receptors interacts with the ECL2 to influence receptor pharmacology by
contributing to ligand binding, receptor activation, and agonist selectivity (Strasser et al., 2008) . Since the publication of the β 2-adrenergic receptor crystal structure, a number of new 7TMR homology models based on this template have been reported. Accurate prediction of the loops, particularly those surrounding the orthosteric binding site, remains one of the more difficult aspects in 7TMR homology modeling. In a previous report of homology models, 5-HT 2B receptors were identified as presenting difficulty in modeling their ECL2 (McRobb et al., 2010) . This has been solved by the recently published crystal structure for the 5-HT 2B
receptor (Wacker et al., 2013) . The E212-R213-F214 residues of the 5-HT 2B receptor form an additional helical turn stabilized by a structured water molecule at the extracellular tip of helix V (Wacker et al., 2013) . As a result, the segment of ECL2 that connect helices III and V via the conserved disulfide bond is shortened in the 5-HT 2B receptor. However, the N-terminus being absent in this crystal structure, further investigations are necessary to fully understand the interactions of the N-terminus with the ECLs/TMs of 5-HT 2B receptors.
The N-terminal regions of 7TMRs have been shown to control the surface expression of receptor proteins, but their effects vary depending on the structural features of each receptor.
Polymorphisms in the β 2-adrenergic receptor (R16G;Q27E) display normal agonist binding and functional coupling to Gs, but markedly alter the degree of agonist-promoted downregulation of receptor expression (Green et al., 1994) . In human β 1-adrenergic receptor, the N-terminal G49 variant was found to display a more profound agonist-promoted downregulation and both basal and agonist-stimulated adenylyl cyclase activity than the S49 variant (Levin et al., 2002) . Here, we show that the increased basal and agonist-stimulated IP activity, gain of function in R6G;E42G receptor coupling is associated with a reduced rate of receptor desensitization, which may participate to this gain of function.
Our study further revealed that not only signal transduction pathways but also desensitization kinetic could be affected by modifying the N-terminus of 5-HT 2B receptors.
Although in vivo validation of these findings have to be performed, it is clear that our findings support the need for modeling 7TMR with their N-terminus and extracellular loops in order to fully understand their activation mechanisms. In conclusion, by using deletion or mutation that leads to a gain of coupling efficiency both in basal and stimulated conditions, our results support that the human 5-HT 2B receptor N-terminus behaves as a negative modulator of the receptor activity. 120±25 fmoles/mg prot for WT, R6G;E42G, R6E;E42R, and Δ Nter, respectively).
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